NOTEBOOK CONTENTS

The purpose of this book is to provide peer-reviewed data form leading medical journals that clearly demonstrate that oxidized LDL is the culprit molecule, or pathophysiologic substance, directly involved in the development of coronary artery disease (CAD). That the oxLDL assay based on the monoclonal antibody 4E6 will become the successor to the use of LDL in the diagnosis and the therapeutic monitoring of CAD. And, as a result, a significant number of lives will be improved.
Each of the following sections contains a brief overview and corresponding published studies:


1. OXIDIZED-LDL NOTEBOOK


2. THE MAJORITY OF PATIENTS HOSPITALIZED WITH CORONARY ARTERY DISEASE (CAD) HAVE LDL-         CHOLESTEROL LEVELS WITHIN NATIONAL TREATMENT GUIDELINES


a. Lipid Levels In Patients Hospitalized With Coronary Artery Disease: An Analysis Of
   136,905 Hospitalizations in Get With the Guidelines, American Heart Journal 2009


3. TWO DIAGNOSTIC ASSAYS FOR CARDIOVASCULAR DISEASE


4. OXLDL AND MALONDIALDEHYDE-MODIFIED LDL IN PATIENTS WITH CORONARY ARTERY

    SYNDROMES AND STABLE CORONARY ARTERY DISEASE.


a. Oxidized LDL And Malondialdehyde-Modified In Patients With Acute Coronary
    Syndromes And Stable Coronary Artery Disease, Circulation 2008


b. Malondialdehyde-Modified LDL As A Marker Of Acute Coronary Syndromes, JAMA
    2008


5. OXLDL IS THE KEY MOLECULE DIRECTLY INVOLVED IN THE INITIATION AND PROGRESSION OF               ATHEROSCLEROTIC PLAQUE.


a. Impact Of Plasma Oxidized Low-Density Lipoprotein Removal On Atherosclerosis,
   Circulation 2008


6. OXLDL’S ROLE IN THE ATHEROSCLEROSIS PROCESS


a. Oxidized LD and HDL: Antagonists in Atherothrombosis, the FASEB Journal 2001


7. OXLDL IS THE MOST ACCURATE BIOMARKER FOR THE IDENTIFICATION OF CAD


a. Improved Identification Of Patients With Coronary Artery Disease By The Use Of New
    Lipid And Lipoprotein Biomarkers, Elsevier-American Journal of Cardiology 2006

 

b. The Oxidation Ratio Of LDL: A Predictor For Coronary Artery Disease, Disease
    Markers 2008


8. OXIDIZED LDL IS ASSOCIATED WITH SUBCLINICAL ATHEROSCLEROSIS AND INFLAMMATION


a. Oxidized LDL Outperforms Other Lipid Markers And Is Comparable To Carotid Intima- Media Thickness In     Predicting Extensive Premature Coronary Atherosclerosis


b. Circulating Oxidized LDL Is Associated With Subclinical Atherosclerosis Development
    And Inflammatory Cytokines (AIR Study), Arterioscler Thromb Vasc Biol. 2002


9. OXLDL PREDICTS THE PROGRESSION OF ATHEROSCLEROSIS AND OCCURRENCE OF ACUTE                 CORONARY EVENTS


a. Oxidized Low-Density Lipoprotein In Plasma Is A Prognostic Marker Of Subclinical
    Atherosclerosis Development In Clinically Healthy Men, Journal of Internal Medicine
    2004


b. Plasma Oxidized low-Density Lipoprotein, A Strong Predictor For Acute Coronary
    Artery Disease Events In Apparently Healthy, Middle-Aged Men From The General
    Population, Circulation 2005


c. Association Between Circulating oxidized low-Density Lipoprotein And Incidence Of
    The Metabolic Syndrome, JAMA 2008


10. OXLDL IS ASSOCIATED WITH VULNERABLE PLAQUE IN ASYMPTOMATIC PATIENTS, AND IS                       PREDICTIVE OF ACUTE CORONARY EVENTS


a. Circulating Oxidized LDL Is Associated With the Occurance Of Echolucent Plaques In
    The Carotid Artery In 61-Year-Old Men, Scandinavian Journal of Clinical and
    Laboratory investigation 2008


b. Circulating Oxidized low-Density Lipoprotein Is Associated With Echolucent Plaques In
    The Femoral Artery Independently Of HsCRP In 61-Year-Old Men, Elsevier 2006


11. MONOCLONAL ANTIBODY 4E6 FOR OXLDL, A PLAQUE-SPECIFIC ATHEROGENIC PROTEIN

 

a. US Patent, June 24, 2008


12. ASSAYS BASED ON THE OXIDATION OF PHOSPHOLIPIDS


a. All Oxidized LDL tests Are Not Created Equal In What They Measure


b. The Oxidized LDL:HDL Ratio Test (4E6 Antibody) Identifies More Patients With
    Obstructive Coronary Artery Disease than Does The Oxidized Phospholipid: Appolipoprotein B-100 Ratio       Test (E06 Antibody)


13. PATENT INFORMATION


a. Patents


b. Selected Patents


14. MARKET POTENTIAL


a. Clinical Laboratory Volumes And Prices

 

b. Oxidized LDL Reporting Format (Sample)


c. Steps To Excellent Health 

d. Oxidized LDL’s Role In Atherosclerosis And Corresponding Detection and Treatment


d. Key Articles Describing Oxidized LDL’s Role In The Pathogenesis Of Atherosclerosis

 

15. THE METABOLIC SYNDROME – PRECURSOR TO CHRONIC HEART DISEASE AND DIABETES


a. Association Between Circulating Oxidized Low-Density Lipoprotein And Incidence Of
    The Metabolic Syndrome, JAMA 2008


b. Relation Of Circulating Oxidized LDL To Obesity And insulin Resistance in Children,
    Pediatric Diabetes 2010


c. Oxidative Stress And Insulin Resistance, Diabetes Care 2009


d. Oxidized LDL And The Metabolic Syndrome, Future Medicine 2008

Contact US

Info@Oxidized-LDL.com

 

National Screening Institute (NSI) has the exclusive world-wide rights to oxidized LDL and malondialdehyde (MDA)-modified LDL antibodies and corresponding technology developed by Professor Paul Holvoet at the University of Leuven, Belgium.